CN Patent

CN1988915A — 用于性功能障碍的多药治疗

Assigned to Palatin Technologies Inc · Expires 2007-06-27 · 19y expired

What this patent protects

本发明公开了用于治疗包括男性勃起功能障碍在内的性功能障碍的多药治疗，其中顺序地给予V型磷酸二酯酶抑制剂(PDE－5)如西地那非和黑皮质素(melanocortin)3和/或4受体激动剂如Ac－Nle－环(－Asp－His－D－Phe－Arg－Trp－Lys)－OH(PT－141)，优选其中通过口服剂量方式给予所述PDE－5抑制剂，优选其中将所述PT－141配制成通过鼻内方式给予，还优选其中在PT－141之前给予所述PDE－5抑制剂。

USPTO Abstract

本发明公开了用于治疗包括男性勃起功能障碍在内的性功能障碍的多药治疗，其中顺序地给予V型磷酸二酯酶抑制剂(PDE－5)如西地那非和黑皮质素(melanocortin)3和/或4受体激动剂如Ac－Nle－环(－Asp－His－D－Phe－Arg－Trp－Lys)－OH(PT－141)，优选其中通过口服剂量方式给予所述PDE－5抑制剂，优选其中将所述PT－141配制成通过鼻内方式给予，还优选其中在PT－141之前给予所述PDE－5抑制剂。

Drugs covered by this patent

bremelanotide-acetate (BREMELANOTIDE ACETATE)

Patent Metadata

Patent number: CN1988915A
Jurisdiction: CN
Classification: —
Expires: 2007-06-27
Drug substance claim: No
Drug product claim: No
Assignee: Palatin Technologies Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.